Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 135 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06919341Recruiting
Spanish immune thrombocytopenia registry
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
A Coruña, A CoruñaAges 2 months+ - NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT07586813RecruitingPhase 2
Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
BeijingAges 18 years+ - NCT07441720RecruitingPhase 2
Umbilical cord blood for low platelets after cancer treatment
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
Hangzhou, ZhejiangAges 12–65 - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT04800458Recruiting
Testing antibody findings to confirm autoimmune low platelets
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
PessacAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT07788456RecruitingPhase 4
Sequential combination therapy for newly diagnosed ITP in adults
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
TianjinAges 18–75 - NCT07786077Recruiting
Patient preferences for ITP treatment
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
East Hanover, New JerseyAges 18 years+ - NCT04598750Recruiting
Assessing bleeding risk in very premature babies with low platelets
This trial looks at how to estimate bleeding risk in newborns who are very premature and have a low platelet count. The goal is to guide safer care by better identifying which babies may be at higher risk of bleeding.
Boston, MassachusettsAges 1 day+ - NCT05931718Recruiting
Track diagnosis and treatment in autoimmune blood count disorders
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
MilanAges 18 years+ - NCT07700238RecruitingPhase 3
Romiplostim plus steroids vs steroids alone for newly diagnosed ITP
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
Long Beach, CaliforniaAges 18–100 - NCT06673498RecruitingPhase 2
Two drugs to raise platelets before surgery in liver disease
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
Fuyang, AnhuiAges 18 years+ - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT06715215Recruiting
Blood test study for immune thrombocytopenia
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
Sohag, SahagAges 1–50 - NCT07587723Recruiting
Real-world study of eltrombopag treatment in immune thrombocytopenia
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
BaselAges 18–100 - NCT07559331RecruitingPhase 3
Dexamethasone plus Orelabrutinib for newly diagnosed immune thrombocytopenia
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Jinan, ShandongAges 18–80 - NCT07535645RecruitingPhase 1/Phase 2
Baricitinib for Low Platelet Counts After Bone Marrow Transplant
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07492693RecruitingPhase 2
Preventing low platelets from chemo in GI cancers
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
ShanghaiAges 18 years+ - NCT07446491RecruitingPhase 1/Phase 2
PN20 for low platelets in liver disease patients needing a procedure
This study tests a new medicine called PN20 to safely raise platelet counts in people with chronic liver disease who need a minor procedure (like a biopsy). It's for patients whose platelet count is below 50 and whose liver disease is not too severe.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 135 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.